CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares shot up 2.2% on Monday . The company traded as high as $2.39 and last traded at $2.30, with a volume of 63,018 shares trading hands. The stock had previously closed at $2.25.

A number of research firms have recently weighed in on CBAY. Zacks Investment Research raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. HC Wainwright reaffirmed a “buy” rating on shares of CymaBay Therapeutics in a report on Thursday, May 12th. Finally, Roth Capital assumed coverage on shares of CymaBay Therapeutics in a report on Friday, July 1st. They issued a “buy” rating for the company.

The firm’s market capitalization is $54.16 million. The company has a 50-day moving average of $1.84 and a 200-day moving average of $1.78.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, analysts predict that CymaBay Therapeutics Inc. will post ($1.20) earnings per share for the current year.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.